Latest from UPMC Physician Resources

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.
Coexisting mutations in BRAF and TERT may be associated with an aggressive phenotype and higher recurrence rates for patients with locally advanced well-differentiated thyroid cancers.
The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.
Umamaheswar Duvvuri, MD, PhD, Assistant Professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well differentiated thyroid cancers.
OncLive® and UPMC CancerCenter, partner with University of Pittsburgh Cancer Institute, have teamed up under OncLive's Strategic Alliance Partnership program.
James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).
Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).
Publication Bottom Border
Border Publication
x